SMARCD1

Across TCGA pan-cancer cohorts, SMARCD1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SMARCD1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SMARCD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SMARCD1 is over-expressed in tumor, although a few such as COAD and CCRCC show the opposite, repressed pattern.

HNSC, LSCC, and COAD are the cancer types where SMARCD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMARCD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.382	<.001	8	view →
LSCC	Male	All	+0.382	<.001	8	view →
COAD	All	All	−0.172	.020	4	view →
CCRCC	Male	II,III,IV	−0.097	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SMARCD1–HNSC

Open the HNSC breakdown →